医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region

2016年06月09日 PM06:54
このエントリーをはてなブックマークに追加


 

SINGAPORE

Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and MSD have embarked on a multi-year partnership for Menarini Asia-Pacific to assume the sales, marketing and distribution of a number of MSD’s pharmaceutical brands in Asia-Pacific since January 2016.

The partnership involves six (6) countries, namely Malaysia, Singapore, Philippines, Hong Kong, Brunei and Macao with annual sales in excess of USD70 million1 that could potentially extend to other key Asia-Pacific markets. The partnership covers a portfolio of highly recognized brands among physicians and patients, ranging from Cardiology, Respiratory and Women’s Health to Central Nervous System and Dermatology. Prior to this agreement, Menarini and MSD had already developed similar partnerships in several other markets in Europe.

“Menarini is excited about the extended partnership to the Asia-Pacific Region that will serve to further strengthen our global collaboration with MSD. MSD is a partner that shares the same core values of upholding a culture of integrity and maintaining the highest ethical standards in the way we do business. The MSD portfolio both complements our existing brands and expands our therapeutic categories and, thanks also to our extensive presence and capabilities in the Region, I am confident that that it will allow us to speed up our growth, said Dr. Luca Lastrucci, CEO of Menarini Asia-Pacific.

“Menarini has been a reliable partner for MSD with similar shared values, a strong sales and marketing footprint, and an excellent track record across the region. We are confident they will grow these brands and increase access for patients to these important medicines,” said Jan Van Acker, President, MSD Asia-Pacific.

About Menarini Asia-Pacific

Menarini Asia-Pacific is a member of the Menarini Group, the world’s largest Italian biopharmaceutical company, and provides physicians and healthcare professionals with medical and scientific information with competence, correctness and the highest ethical standards in all its work processes”. Menarini has the heritage of over 130 years and over 16,000 employees in more than 100 countries. Menarini Asia-Pacific’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Cardiovascular, Oncology/Specialty Care and Men’s Health.

For more information about Menarini Asia-Pacific, please visit: www.menariniapac.com

1 IMS MIDAS MAT Q4 2015

View source version on businesswire.com: http://www.businesswire.com/news/home/20160609005549/en/

CONTACT

For A. Menarini Asia-Pacific Holdings Pte Ltd:
Jennifer Lin,
+65-64943427
Senior Regional Corporate Branding & Communications
Manager
JenniferCW.lin@menariniapac.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics